![中国临床肿瘤学会(CSCO)恶性血液病诊疗指南·2020](https://wfqqreader-1252317822.image.myqcloud.com/cover/547/33145547/b_33145547.jpg)
上QQ阅读APP看书,第一时间看更新
2.5 治疗
2.5.1 诱导缓解治疗
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image141.jpg?sign=1739479681-HCfnyPQFaMSnejntKzxK25FgdHj8jLba-0-e6ff2079940162beb965a5f3927d3b92)
所有急性髓系白血病患者,可以参加临床研究的情况下,均建议首选参加临床研究。在没有临床研究的情况下,可以参照下述建议进行治疗。本章节为年龄<60岁成人患者。
2.5.2 诱导治疗后检测
诱导治疗过程中,建议在骨髓抑制期(停化疗后第7~14天左右)、恢复期(停化疗后第21~28天左右)复查骨髓。根据骨髓抑制期、血象恢复期的骨髓情况进行治疗调整。
(1)标准剂量Ara-C诱导后治疗监测
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image142.jpg?sign=1739479681-yVAu8kgh6xFFRkarHdhCyODFaiTy2tKQ-0-9ec12ca67531f6f8e17ea5cc5da1ad6d)
标准剂量Ara-C诱导后治疗监测(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image143.jpg?sign=1739479681-0ALcZKgQFawZ3mAn5Tu9eBjtJE9rYaJP-0-3708bfd4ee8edd90992d90672b67c7f7)
标准剂量Ara-C诱导后治疗监测(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image144.jpg?sign=1739479681-agmfwHfjzq5njfZQ3iFYFh6zM5pdLVav-0-357d52258d042d075ecae2fbde1ab41b)
(2)含中大剂量Ara-C方案的诱导后治疗监测
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image145.jpg?sign=1739479681-EhACuIUnGlMm4Oe3tR2XVKTEnZ3EkQyx-0-168329d1c3578ce477f92d0f6a7fcfee)
2.5.3 AML完全缓解后治疗的选择
按遗传学预后危险度分组治疗
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image146.jpg?sign=1739479681-epwwvvCgYL2zRvwg14DQYxyitDH3hJA2-0-4f4c03ee3909036fbfa4bbc09343df90)
按遗传学预后危险度分组治疗(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image147.jpg?sign=1739479681-lDOIzJ1KHV9XBAwH8UzAUNGt3t3IY7Ag-0-8315099d711c4cd6174c52c4f43fb9cb)
按遗传学预后危险度分组治疗(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image148.jpg?sign=1739479681-swN74izqYDoNHSB6B2BuiQXnDBtLB2GL-0-f026d1d3c1e93b35d5b22af3777130de)